At the moment, only patients in hospital with flu-like symptoms are being routinely tested for the virus.
However, there have been calls to do more tests, especially for NHS staff and other key workers
The test being used is known as a PCR test. A swab from your throat or nose has to be taken and tested in the lab.
But scientists are also looking at tests which can check whether someone has had the disease in the past. These look for markers of immunity called antibodies in the blood.
They are faster than PCR tests, using a drop of blood on a device a bit like a pregnancy test.
This could help work out how widespread the disease has been and whether people are safe to go back to work
Straight from the horse’s mouth—both sides
by Jon Rappoport
March 24, 2020
“Positive [test] results are indicative of active infection with 2019-nCoV but do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities.”
I’m going to blow past the blatant contradiction in that CDC paragraph and cut to the chase.
The key line in that paragraph is: “The agent detected [the coronavirus] may not be the definite cause of disease.”
R0 is the basic case reproduction number.
“It’s the average number of successful transmissions per case when everyone in the population is susceptible.
While R0 is above one, case numbers would increase. If R0 equals one, case numbers are stable– on average, each case gives rise to just one more case. And when R0 is less than one, case numbers decrease. So it’s clearly important to know what R0 is. For COVID-19, because it’s caused by a new virus, SARS-CoV-2, we can assume everyone is susceptible. We can estimate R0 by looking at the average number of secondary cases per case– if we can find chains of transmission– or from looking at how cases increase in the population over time, which is known as the epidemic curve. An epidemic curve is a bar chart of cases by time.
Professor Judith Glynn
RO for COVID-19 ~ 1.5 to 4.5 (Avg 3.0)
R0 for Measles ~ 15
R0 for Chickenpox ~ 10
R0 for SARS ~ 3
R0 for Ebola ~ 2
R0 for flu ~ 1.5-3 (Avg 2.25)
Source: London School of Hygiene and Tropical Medicine
Note: My focus in recent posts was to understand the numbers and keywords used by these health experts. I need to comprehend their narrative to debunk it.
As Jon Rappaport points out, the VIRUS is a convenient smokescreen for agendas and corporate ills.
As can be seen from their own experts COVID-19 “on average” is comparable to seasonal flu or SARS-1.
So we have to ask why the overbearing and excessive mechanisms of the state are being used to respond to this “pandemic”? There are multiple solutions (outcomes) for the globalist oligarchs and supranational criminals from the “covid-19 virus” scare!
I think it will be worth my time to compile the multiple outcomes that result from the bull excrement called the “Covid-19 Pandemic”
Note: With a population of 63millions and an infection penetration of 80% in the UK population, if we use a 1% mortality rate, we get potentially 90,982 deaths. These deaths are focused on the 18% of the population that are over 65years old.
The calculator allows you to change your numerical assumptions(estimates).
Inovio’s proprietary platform is leading the way forward for activation immunotherapy. This one-of-a-kind platform delivers optimized DNA into cells, where it is translated into proteins that activate an individual’s immune system to generate a robust targeted T cell and antibody response. Inovio’s technology has generated impressive results in preclinical and clinical studies. VGX-3100, a product using the platform technology, has entered Phase 3 trials as the first immunotherapy for HPV-related cervical precancer.
Novavax, Inc. is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Using innovative proprietary recombinant nanoparticle vaccine technology, we produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats. Our vaccine candidates are genetically engineered three-dimensional nanostructures that incorporate recombinant proteins critical to disease pathogenesis.